Excepgen GTM brain

category

market profile

• text: RNA vaccine developers face tradeoffs involving immune responses, formulation and tolerability.
• text: The company has shifted its public emphasis from protein production for discovery at its 2019 launch to nucleic acid therapeutics.
• text: Published work reports preclinical research by ExcepGen-affiliated authors; this is not evidence of clinical efficacy.

personas

• title: Head of RNA vaccine research
  pains:

  • Managing unwanted innate responses while preserving an effective immune response
  • Generating candidate-specific tolerability and formulation data
• title: Biopharma business development lead
  pains:

  • Finding differentiated RNA platform opportunities with credible translational evidence
  • Assessing patent rights, integration and development risk
• title: Translational research director
  pains:

  • Bridging preclinical vaccine results to a viable human development program
  • Comparing experimental results with existing delivery and RNA technologies

icp

• text: Potential partners are vaccine and biopharmaceutical teams developing conventional or amplifying RNA candidates; actual customer and commercial terms are not disclosed.
• text: Research organizations studying RNA medicines and cellular responses may be relevant collaborators, irrespective of company size.

message pillars

• text: Pursue more tolerable RNA medicines.
• text: Address cellular response to nucleic acids.
• text: Work across multiple vaccine formats.

objections

• objection: Is better tolerability established in humans?
  response: Review the published research and ask for the clinical development stage and candidate-specific data; avoid assuming clinical proof.
• objection: How would this work with an existing RNA program?
  response: Discuss formulation, manufacturing, IP and experimental compatibility directly with the team.
• objection: Does reducing reactogenicity compromise the desired response?
  response: Review the relevant experimental endpoints and independent replication for the intended vaccine.

competitors

• name: Orna Therapeutics
  why: Develops RNA therapeutic technology and is an adjacent platform alternative.
• name: BioNTech
  why: Develops mRNA medicines and alternative vaccine platforms.
• name: Chimeron Bio
  why: Identified as a possible competitor by Crunchbase; scientific and commercial fit needs validation.

influencers

• name: Thomas Folliard
  url: https://www.oxonianventures.com/portfolio-founder-spotlight/excepgen-founder-thomas-folliard-j2ab6
  why: Founder and CEO explains the nucleic acid medicines vision.

keywords

• mRNA vaccine tolerability
• RNA innate immune response
• self amplifying RNA vaccine
• RNA vaccine reactogenicity
• RNA platform collaboration
• nucleic acid medicines

voice

• Scientific and restrained
• Mechanism-oriented
• Aspirational

signals

• text: A biotech launches an RNA vaccine program and seeks ways to address tolerability.
• text: A vaccine group is researching self-amplifying RNA platforms and reactogenicity.

pricing

motion

channels

• scientific publications
• biotech press

confidence

Founders

• name: Thomas Folliard
  title: Founder
  role: Founder